PL3609319T3 - Modele mysie i cząsteczki terapeutyczne - Google Patents
Modele mysie i cząsteczki terapeutyczneInfo
- Publication number
- PL3609319T3 PL3609319T3 PL18719629.0T PL18719629T PL3609319T3 PL 3609319 T3 PL3609319 T3 PL 3609319T3 PL 18719629 T PL18719629 T PL 18719629T PL 3609319 T3 PL3609319 T3 PL 3609319T3
- Authority
- PL
- Poland
- Prior art keywords
- mouse models
- therapeutic molecules
- therapeutic
- molecules
- models
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1705725.8A GB2561352B (en) | 2017-04-10 | 2017-04-10 | Animal models and therapeutic molecules |
| PCT/GB2018/050946 WO2018189520A1 (en) | 2017-04-10 | 2018-04-10 | Animal models and therapeutic molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3609319T3 true PL3609319T3 (pl) | 2025-06-02 |
Family
ID=58744850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18719629.0T PL3609319T3 (pl) | 2017-04-10 | 2018-04-10 | Modele mysie i cząsteczki terapeutyczne |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200056202A1 (pl) |
| EP (2) | EP3609319B1 (pl) |
| JP (3) | JP2020512840A (pl) |
| CN (1) | CN111031789A (pl) |
| BR (1) | BR112019021252A2 (pl) |
| CA (1) | CA3059513A1 (pl) |
| DK (1) | DK3609319T3 (pl) |
| ES (1) | ES3015425T3 (pl) |
| FI (1) | FI3609319T3 (pl) |
| GB (1) | GB2561352B (pl) |
| PL (1) | PL3609319T3 (pl) |
| PT (1) | PT3609319T (pl) |
| WO (1) | WO2018189520A1 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| CN103025884B (zh) | 2010-07-26 | 2015-11-25 | 特里安尼公司 | 转基因动物和使用方法 |
| US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| EP4414484A3 (en) | 2016-02-04 | 2025-01-15 | Trianni, Inc. | Enhanced production of immunoglobulins |
| GB2578867A (en) * | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| CN114502725B (zh) * | 2019-07-01 | 2025-09-12 | 特里安尼公司 | 转基因哺乳动物及使用方法 |
| GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| GB202104943D0 (en) | 2021-04-07 | 2021-05-19 | Petmedix Ltd | A method for identifying lead sequences |
| CN117651486A (zh) * | 2021-05-05 | 2024-03-05 | 利威瑞健股份有限公司 | 用于生产抗体的工程改造的非人动物 |
| WO2022235759A1 (en) * | 2021-05-05 | 2022-11-10 | Trianni, Inc. | Transgenic rodents expressing chimeric equine-rodent antibodies and methods of use thereof |
| CA3218564A1 (en) * | 2021-05-05 | 2022-11-10 | Leveragen, Inc. | Engineered non-human animals for producing antibodies |
| GB202107372D0 (en) | 2021-05-24 | 2021-07-07 | Petmedix Ltd | Animal models and therapeutics molecules |
| JP2024526122A (ja) * | 2021-06-17 | 2024-07-17 | ペットメディックス・リミテッド | 抗イヌcd20抗体 |
| KR20240110577A (ko) * | 2021-11-10 | 2024-07-15 | 트리아니, 인코포레이티드 | 유전자이식 포유동물 및 이의 사용 방법 |
| KR20240139085A (ko) | 2022-02-09 | 2024-09-20 | 펫메딕스 리미티드 | 치료 항체 |
| GB202209247D0 (en) | 2022-06-23 | 2022-08-10 | Petmedix Ltd | Animal models and therapeutic molecules |
| GB202217993D0 (en) | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Therapeutic antibodies |
| GB202217978D0 (en) | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
| JP2026508096A (ja) | 2023-01-20 | 2026-03-10 | ゾエティス・サービシーズ・ユーケー・リミテッド | 治療抗体 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU632843B2 (en) * | 1989-08-10 | 1993-01-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin |
| AU640397B2 (en) * | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
| ATE158021T1 (de) * | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US7261890B2 (en) * | 2001-12-21 | 2007-08-28 | Idexx Laboratories, Inc. | Methods for using canine immunoglobulin variable domains and caninized antibodies |
| HUE026260T2 (en) * | 2003-11-21 | 2016-06-28 | Ucb Biopharma Sprl | A method for treating multiple sclerosis by inhibiting IL-17 activity |
| US8722587B2 (en) * | 2008-04-09 | 2014-05-13 | The Trustees Of The University Of Pennsylvania | Single chain fragment variable antibody libraries and uses thereof |
| DK3622815T3 (da) * | 2009-07-08 | 2023-06-26 | Kymab Ltd | Gnavermodeller og terapeutiske molekyler |
| ES2984483T3 (es) * | 2010-03-31 | 2024-10-29 | Ablexis Llc | Ingeniería genética de ratones para la producción de anticuerpos quiméricos |
| US10662256B2 (en) * | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| CN103025884B (zh) * | 2010-07-26 | 2015-11-25 | 特里安尼公司 | 转基因动物和使用方法 |
| GB2495083A (en) * | 2011-09-26 | 2013-04-03 | Kymab Ltd | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates |
| CA2875783C (en) * | 2012-06-06 | 2018-12-11 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
| US11116795B2 (en) * | 2015-07-10 | 2021-09-14 | The Trustees Of The University Of Pennsylvania | Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor |
-
2017
- 2017-04-10 GB GB1705725.8A patent/GB2561352B/en active Active
-
2018
- 2018-04-10 JP JP2020504455A patent/JP2020512840A/ja active Pending
- 2018-04-10 PL PL18719629.0T patent/PL3609319T3/pl unknown
- 2018-04-10 BR BR112019021252-3A patent/BR112019021252A2/pt unknown
- 2018-04-10 WO PCT/GB2018/050946 patent/WO2018189520A1/en not_active Ceased
- 2018-04-10 PT PT187196290T patent/PT3609319T/pt unknown
- 2018-04-10 CN CN201880038549.6A patent/CN111031789A/zh active Pending
- 2018-04-10 ES ES18719629T patent/ES3015425T3/es active Active
- 2018-04-10 DK DK18719629.0T patent/DK3609319T3/da active
- 2018-04-10 EP EP18719629.0A patent/EP3609319B1/en active Active
- 2018-04-10 US US16/604,120 patent/US20200056202A1/en active Pending
- 2018-04-10 EP EP25155602.3A patent/EP4560012A3/en active Pending
- 2018-04-10 FI FIEP18719629.0T patent/FI3609319T3/fi active
- 2018-04-10 CA CA3059513A patent/CA3059513A1/en active Pending
-
2023
- 2023-05-10 JP JP2023078065A patent/JP2023104949A/ja active Pending
-
2025
- 2025-04-02 JP JP2025061261A patent/JP2025107178A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111031789A (zh) | 2020-04-17 |
| GB2561352A (en) | 2018-10-17 |
| DK3609319T3 (da) | 2025-03-31 |
| GB201705725D0 (en) | 2017-05-24 |
| US20200056202A1 (en) | 2020-02-20 |
| BR112019021252A2 (pt) | 2020-05-12 |
| EP4560012A2 (en) | 2025-05-28 |
| CA3059513A1 (en) | 2018-10-18 |
| EP4560012A3 (en) | 2025-07-30 |
| JP2020512840A (ja) | 2020-04-30 |
| ES3015425T3 (en) | 2025-05-05 |
| FI3609319T3 (fi) | 2025-03-27 |
| JP2025107178A (ja) | 2025-07-17 |
| JP2023104949A (ja) | 2023-07-28 |
| GB2561352B (en) | 2023-01-18 |
| WO2018189520A1 (en) | 2018-10-18 |
| EP3609319A1 (en) | 2020-02-19 |
| EP3609319B1 (en) | 2025-02-26 |
| PT3609319T (pt) | 2025-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3609319T3 (pl) | Modele mysie i cząsteczki terapeutyczne | |
| HUS2400028I1 (hu) | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások | |
| HUS2500022I1 (hu) | Terápiás ellenanyagok és alkalmazásaik | |
| IL256179A (en) | lag-3 binding molecules and methods of using them | |
| SG10201802295XA (en) | Animal Models and Therapeutic Molecules | |
| GB201816442D0 (en) | Animal models and therapeutic molecules | |
| PT3582838T (pt) | Inaladores e métodos relacionados | |
| SG11201708624YA (en) | Therapeutic antibodies and uses thereof | |
| PT3582839T (pt) | Inalador | |
| IL270011B (en) | Medicinal compounds and methods | |
| PT3582837T (pt) | Inaladores | |
| IL257932A (en) | Adapted cytotoxins and their therapeutic uses | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| GB201600559D0 (en) | Therapeutic molecules | |
| GB201317447D0 (en) | Animal models and therapeutic molecules |